Taking into account that the use of specific FXR agonist is suggested as a promising therapy in a broad spectrum of diseases, including hepatic failure, metabolic syndrome, diabetes, obesity, or vascular impairment occurring in liver cirrhosis [16,44,45,46], our data contribute to the idea that strengthening of FXR/SHP signaling may be beneficial in the treatment of the ALF. This evidence concerns the gene NR0B2 and obesity due to melanocortin 4 receptor deficiency.